BioCentury
ARTICLE | Company News

Celgene, NanoString deal

June 9, 2014 7:00 AM UTC

NanoString will develop an in vitro companion diagnostic using its nCounter Analysis System to screen patients for a pivotal trial of Revlimid lenalidomide in diffuse large B cell lymphoma (DLBCL). The trial is slated to start in late 2014 or early 2015. NanoString will receive a $5.8 million upfront payment and is eligible for $17 million in developmental and regulatory milestones. The company is also eligible for up to $22.5 million in commercial milestones if the diagnostic's sales do not exceed undisclosed minimum annual revenues during the first three years after approval. NanoString will be responsible for development, regulatory approval and commercialization of the test and can independently develop it for additional indications. The nCounter system is an automated system for digital gene expression analysis. NanoString declined to disclose details, and Celgene could not be reached. ...